David Elkin, MD, Erick Hung, MD, and Gilbert Villela, MD
The rapidly evolving field of neuroethics is concerned with the ethical questions that new technologies will pose about autonomy, privacy, the definition of normal, and individuality.
Whether or not to inform patients of off-label drug prescribing has been the subject of heated debate for a long time, with convincing arguments made on both sides of the issue and no consensus reached.
Conflicts between federal and state laws governing marijuana, lack of evidence about its efficacy as a treatment, and physicians' inability to predict or control dosage would all be aided by reclassification of the drug that would let clinical research go forward.
There is increasing evidence that cannabis may represent a useful alternative or adjunct in the management of painful peripheral neuropathy, a condition that can markedly affect life quality.
Today's medical students have an important role in ethical care for the dying because their role involves having conversations with patients about their experiences and values.
Though there are channels through which terminally ill patients can access some experimental drugs that have not yet received FDA approval for marketing to the public, in general those drugs must already be proven safe and effective.
This month theme issue editor, Trahern Jones, a fourth-year student at Mayo Medical School in Rochester, Minnesota, spoke with Dr. Edward Laskowski about the use of performance-enhancing drugs and substances among athletes today.